Close Menu

Ian Clark

Jan 06, 2017

Guardant Health has appointed Ian Clark to its board of directors. Clark joins Guardant Health from Genetech, where he served as CEO, and Roche, where he led North American commercial operations. He has also held leadership roles at Novartis, Sanofi, and Ivax.

More Like This

Oct 08, 2020

Caris Life Sciences: Brian Lamon

Caris Life Sciences has appointed Brian Lamon as its chief business officer and head of biopharma business development. Lamon brings over 15 years of experience from large pharma and academia to the firm. He previously worked for Bristol Myers Squibb as a VP and development lead. Prior to that, he held several leadership roles in clinical development and business development for the same company.

Before joining industry, Lamon was assistant dean of research development and an assistant professor in the department of pathology and laboratory medicine at Weill Medical College of Cornell University in New York. He remains active on the faculty through a courtesy appointment as assistant professor.

Oct 08, 2020

Proscia: Monica Santamaria-Fries

Proscia announced Monica Santamaria-Fries has joined the company as digital transformation officer. She has been with The Permanente Medical Group (TPMG) for more than 30 years, including as chief of pathology at the Kaiser Foundation Hospital in Santa Clara, California. She also was clinical lab director and assistant chair for the Regional TPMG Pathology Department.

Oct 07, 2020

Nobel Prize: Emmanuelle Charpentier, Jennifer Doudna

Emmanuelle Charpentier and Jennifer Doudna have been jointly awarded the 2020 Nobel Prize in chemistry for their discovery and development of the CRISPR/Cas9 genome editing method.

"There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments," said Nobel Committee for Chemistry Chair Claes Gustafsson in a statement.

Charpentier is the director of the Max Planck Unit for the Science of Pathogens in Berlin. She holds a PhD from the Institute Pasteur in France.

Doudna is a professor at the University of California, Berkeley, and a Howard Hughes Medical Institute investigator. She holds a PhD from Harvard Medical School.

The two Nobel laureates will equally share the 10 million Swedish kronor ($1.12 million) award.

Oct 06, 2020

Pillar Biosciences: Robert Forrester

Pillar Biosciences, a next-generation sequencing cancer diagnostics company, has added Robert Forrester as an independent board member. Forrester has previously served as CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. He is also cofounder and chief experience officer of EQRx, which makes innovative medicines at dramatically lower prices for the benefit of society. Forrester has also served as managing director of the Proprietary Investment Group at MeesPierson.

Oct 06, 2020

Helio Health: Wei Li

Helio Health has appointed Wei Li to its advisory board. Li has more than 20 years of experience in bioinformatics research and development and is currently the endowed chair and professor of bioinformatics for the biological chemistry department at the University of California, Irvine's School of Medicine. He previously was the Dan L. Duncan Chair professor in the division of biostatistics at the Dan L. Duncan Cancer Center as part of the molecular and cellular biology department at the Baylor College of Medicine.

Oct 06, 2020

Karius: Alexander Ford

Karius has appointed Alexander (Alec) Ford as CEO. Ford most recently served as chief operating officer of Myriad Genetics. He will replace current CEO Mickey Kertesz, who will transition to the roles of president and chief product officer.

Oct 05, 2020

Myriad Genetics: Alexander Ford

Myriad Genetics said in a filing with the US Securities and Exchange Commission that Alexander Ford has resigned as chief operating officer as of Oct. 2. Before recently becoming chief operating officer, he was president of Myriad's women's health division and president of Myriad Genetic Laboratories. Prior to joining Myriad in 2010, Ford worked in various leadership roles in sales, business development, and product marketing at Novartis, Sanofi Aventis, Nektar Therapeutics, and Pfizer.

Oct 02, 2020

Tempus: Christopher Mason

Christopher Mason is planning to take a leave of absence from his post as associate professor in the Department of Physiology and Biophysics at Weill Cornell Medicine to work on COVID-19 testing, including at Tempus, Biotia, and labs in Wisconsin and New York City. Chicago-based Tempus said in June that Mason has joined the firm as VP of emerging genome technology. He holds a PhD in genetics from Yale University and a dual BS degree in genetics and biochemistry from the University of Wisconsin-Madison.

Oct 01, 2020

Thrive Earlier Detection: Sam Asgarian, Frank Diehl, Dina Ciarimboli

Thrive Earlier Detection has appointed Sam Asgarian is its new chief medical officer, Frank Diehl as executive vice president of product solutions, and Dina Ciarimboli as chief legal officer.

Asgarian will lead the firm's medical strategy, including the integration of its CancerSEEK early detection test into routine medical care. He was most recently vice president of CVS Health's Transformation Health Product organization. Asgarian joined CVS as part of the Aetna acquisition, having served as the chief medical officer of Aetna's clinical services organization, overseeing medical management and clinical policy operations. He holds a BA in molecular and cell biology from the University of California at Berkeley, an MA in medical sciences from Loyola University Chicago, an MD from Tulane University, and an MBA from Cornell University.

Diehl is a globally recognized leader in cancer biology and detection who has pioneered the use of circulating tumor DNA to detect and track the progression of cancer. In 2008, he cofounded liquid biopsy firm Inostics, where he served as chief scientific officer through its acquisition by Sysmex, ultimately becoming CEO of Sysmex Inostics. Diehl completed his postdoc at the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and worked in the laboratory of Thrive cofounders Bert Vogelstein and Kenneth Kinzler. He holds a PhD in molecular pathology from Ruprecht-Karls University in Heidelberg, Germany.

Ciarimboli's appointment follows her interim role as general counsel. Prior to joining Thrive full time, she was general counsel at Third Rock Ventures. Before that, she served as general counsel to several venture capital firms focused on early-stage investing in various industries including biotech, diagnostics, medical devices, and healthcare services. Earlier, she served as an associate at Testa, Hurwitz & Thibeault, and as a senior associate at PricewaterhouseCoopers. Ciarimboli holds a BA in accounting and philosophy from Boston College and a JD from Boston College School of Law.

Sep 29, 2020

BioAffinity Technologies: Martin Tammemägi

BioAffinity Technologies announced Martin Tammemägi will become chairman of the company's scientific and medical advisory board. He was a co-investigator and remains active in the US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, the US National Lung Screening Trial, and the Pan-Canadian Early Detection of Lung Cancer Study. He is an active associate member of the US National Institutes of Health National Cancer Institute Cancer Intervention and Surveillance Modeling Network lung group and is the provincial scientific lead for Ontario Health - Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk.

Sep 24, 2020

GenMark Diagnostics: Brian Mitchell

GenMark Diagnostics said in a filing with the US Securities and Exchange Commission that Brian Mitchell, its senior vice president of operations, is no longer employed by the company.

Sep 22, 2020

Exact Sciences: Eli Casdin

In a filing with the US Securities and Exchange Comission, Exact Sciences said that board member Eli Casdin had submitted his resignation from the company's board of directors, effective Sept. 21. Casdin is the chief investment officer and founder of Casdin Capital, an investment firm focused on the life sciences and healthcare industry.

Sep 22, 2020

Inivata: Peter Collins

Inivata has appointed Peter Collins as the firm's chief business officer. Prior to Inivata, Collins most recently held senior leadership positions at Guardant Health. He has also served as chief business officer at Yourgene Health. Prior to Yourgene, Collins served as VP, head of diagnostics at GSK, as well as VP of pharma business development at Qiagen. He was also the founder and board member of Epemed. 

Sep 18, 2020

Quidel: Robert Bujarski

Quidel has appointed Robert Bujarski as chief operating officer effective Sept. 14. Bujarski had been Quidel's SVP of commercial operations in North America and general counsel since July 2019, SVP of business development from August 2009 through July 2019, and corporate secretary until February 2019.

Sep 17, 2020

iAssay: Edward Strong

Edward Strong has been named scientific director of iAssay, a firm developing an open platform that consolidates utilization of a range of point-of-care tests with a single cloud-connected, handheld reader. Strong, a geneticist, formerly cofounded and served as CEO of MedGenomics, and also served as interim CEO of LifeGenomix.